| 1 |
NCT00868374 |
Terminated
Has Results |
Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder |
- Major Depressive Disorder
- Generalized Anxiety Disorder
|
- Drug: Quetiapine XR
- Drug: Placebo
|
Interventional |
Phase 3 |
- Keming Gao
- AstraZeneca
- University Hospitals Cleveland Medical Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in 17 Item Hamilton Rating Scale for Depression (HAM-D-17)
|
23 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00868374 |
12-07-29 |
MDD/GAD |
June 2008 |
October 2011 |
October 2011 |
March 25, 2009 |
December 29, 2016 |
February 11, 2014 |
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
|
| 2 |
NCT01325532 |
Completed
Has Results |
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Device: Active CES
- Device: Sham CES
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Fisher Wallace Labs, LLC
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Hamilton Depression Rating Scale (HAM-D 17) Score From Baseline to Week 3
- Reported Side Effects Based on PRISE AE Scores
- Change in Global Sleep Scores on the Pittsburgh Sleep Quality Index (PSQI) From Baseline to Week 3.
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT01325532 |
2010 P000461 |
|
November 2010 |
January 2014 |
January 2015 |
March 29, 2011 |
June 1, 2016 |
June 1, 2016 |
- Depression Clinical and Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 3 |
NCT00705003 |
Completed
Has Results |
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
- Drug: BCI-024 (Buspirone)
- Drug: Matching placebo
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- BrainCells Inc.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6
- The Change From Baseline in the CGI-S at Week 6
- The Change From Baseline in the IDS-C30 at Week 6
- (and 2 more...)
|
142 |
All |
18 Years to 65 Years (Adult) |
NCT00705003 |
CBM-IT-01 |
|
May 2008 |
December 2008 |
December 2008 |
June 25, 2008 |
June 18, 2014 |
June 18, 2014 |
- Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States - Synergy Research Centers
San Diego, California, United States - Atlanta Institute of Medicine & Research, Inc.
Altanta, Georgia, United States - (and 6 more...)
|
| 4 |
NCT01971203 |
Completed
Has Results |
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat |
- Major Depressive Disorder
- Generalized Anxiety Disorder
|
- Drug: seroquel xr
- Behavioral: CBT
|
Interventional |
Not Applicable |
- Icahn School of Medicine at Mount Sinai
- AstraZeneca
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- MADRS
- HAM-A
- Clinical Global Impression Scales for Severity and Improvement
- Changes in Sexual Functioning Questionnaire (CSFQ)
|
62 |
All |
18 Years to 65 Years (Adult) |
NCT01971203 |
GCO 09-0807 |
|
September 2009 |
June 2013 |
June 2013 |
October 29, 2013 |
February 15, 2018 |
February 15, 2018 |
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
| 5 |
NCT00797901 |
Completed |
Depression Treatment in General Medical Settings |
|
- Other: Collaborative Care
|
Interventional |
Not Applicable |
- University of Puerto Rico
- National Institute of General Medical Sciences (NIGMS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Depression
- Health-Related Functional Impairment
- Quality of Life
- (and 2 more...)
|
179 |
All |
18 Years and older (Adult, Senior) |
NCT00797901 |
S06GM008224 |
|
August 2004 |
April 2008 |
April 2008 |
November 25, 2008 |
August 28, 2014 |
|
- University of Puerto Rico
San Juan, Puerto Rico
|
| 6 |
NCT00985725 |
Completed
Has Results |
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: SPD489 (Lisdexamfetamine dimesylate)
- Drug: Matching placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)
- Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)
- Change From Baseline in BRIEF-A T-scores at Week 9, LOCF
- (and 12 more...)
|
143 |
All |
18 Years to 55 Years (Adult) |
NCT00985725 |
SPD489-205 |
|
October 2009 |
April 2011 |
April 2011 |
September 28, 2009 |
March 23, 2015 |
April 6, 2012 |
- Sun Valley Research Center
Imperial, California, United States - Pharmacology Research Center
Los Alamitos, California, United States - Excell Research
Oceanside, California, United States - (and 30 more...)
|
| 7 |
NCT01559324 |
Completed |
Electroconvulsive Therapy (ECT) for Elderly Patients With Major Depression |
|
|
Interventional |
Phase 4 |
- Diakonhjemmet Hospital
- MD Tor Magne Bjølseth
- MD Torfinn Lødøen Gaarden
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression
- Cognitive function
- Blood-tests
|
92 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT01559324 |
6.2009.06 2011/02/0009 |
|
August 2009 |
July 2013 |
November 2013 |
March 21, 2012 |
July 9, 2015 |
|
- Diakonhjemmet Hospital, Department of Old Age Psychiatry
Oslo, Norway
|
| 8 |
NCT00505518 |
Completed
Has Results |
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home |
- Major Depressive Disorder
|
- Drug: Psychotropic medication (at discretion of psychiatrist)
- Behavioral: Collaborative psychiatric and primary medical care
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Mean Scores on Clinical Global Impressions
- Patient/Family Telepsychiatry Service Satisfaction Survey
- Nurse Telepsychiatry Services Satisfaction Questionnaire
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT00505518 |
2006-P-001508 |
|
September 2006 |
November 2007 |
November 2007 |
July 23, 2007 |
September 17, 2013 |
September 17, 2013 |
- Depression and Clinical Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States - South Cove Manor
Boston, Massachusetts, United States
|
| 9 |
NCT03329287 |
Recruiting |
Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression |
- Generalized Anxiety Disorder
- Major Depressive Disorder
|
- Behavioral: SCBT
- Drug: SSRIs and/or SNRIs
- Behavioral: Psychological Placebo
|
Interventional |
Not Applicable |
- Shanghai Mental Health Center
- Changhai Hospital
- Shanghai 10th People's Hospital
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- changes of The Hamilton Depression Scale (HAMD-17)
- changes of The Hamilton Anxiety Scale (HAMA-14)
- changes of The Patient Health Questionnaire (PHQ-9)
- (and 4 more...)
|
180 |
All |
18 Years to 60 Years (Adult) |
NCT03329287 |
15411950201 |
|
July 1, 2017 |
March 30, 2018 |
June 30, 2018 |
November 1, 2017 |
November 1, 2017 |
|
- Shanghai Mental Health Center
Shanghai, Shanghai, China
|
| 10 |
NCT01667926 |
Completed
Has Results |
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Ketamine
- Drug: Placebo
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale - Suicidal Ideation (HDRS-SI)
- HDRS-28 Total
|
37 |
All |
18 Years to 65 Years (Adult) |
NCT01667926 |
2012-P-001042 |
|
January 2013 |
October 2015 |
November 2015 |
August 17, 2012 |
April 20, 2017 |
April 20, 2017 |
- Depression Clinical and Reseach Program - MGH
Boston, Massachusetts, United States
|
| 11 |
NCT02004145 |
Completed |
Trial of a Positive Psychology Intervention in Major Depressive Disorder |
- Major Depressive Disorder
|
- Behavioral: Positive Psychology
- Behavioral: Control Condition
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- American Foundation for Suicide Prevention
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in BHS Scores
- Change in CHRT Scores
- Change in QIDS-SR Scores
|
65 |
All |
18 Years and older (Adult, Senior) |
NCT02004145 |
2013P001234
SRG-2-019-12 |
HOPE |
October 2013 |
September 2015 |
September 2015 |
December 6, 2013 |
April 19, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 12 |
NCT00683852 |
Completed
Has Results |
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy |
- Major Depressive Disorder
|
- Drug: Aripiprazole 5mg
- Drug: Aripiprazole 2mg
- Drug: Placebo
|
Interventional |
Phase 3 |
- Massachusetts General Hospital
- Bristol-Myers Squibb
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate
- MADRS (Montgomery-Asberg Depression Rating Scale) Readmission Rate
- Mean Change in MADRS (Montgomery-Asberg Depression Rating Scale) Score From Baseline to the End of Follow-up
- (and 2 more...)
|
225 |
All |
18 Years to 65 Years (Adult) |
NCT00683852 |
BMS - 2008A053242 |
|
September 2008 |
September 2009 |
September 2009 |
May 26, 2008 |
July 19, 2017 |
July 19, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 13 |
NCT01103271 |
Completed
Has Results |
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder |
- Major Depressive Disorder
|
- Other: Open-label Placebo
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- Harvard University
- National Center for Complementary and Integrative Health (NCCIH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Feasibility
- Pre-Post Efficacy
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT01103271 |
2009p002469
K24AT004095 |
|
May 2010 |
May 2011 |
May 2011 |
April 14, 2010 |
January 14, 2013 |
January 14, 2013 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 14 |
NCT01787240 |
Terminated
Has Results |
Neurobiological Bases of Placebo Response in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Escitalopram 10mg
- Drug: Placebo
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Feasibility
- Effects of Acute Tryptophan Depletion on Mood
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT01787240 |
2012P001241 |
|
November 2012 |
August 2016 |
August 2016 |
February 8, 2013 |
May 16, 2017 |
April 14, 2017 |
- Massachusetts General Hospital Depression Clinical and Research Program
Boston, Massachusetts, United States
|
| 15 |
NCT01613820 |
Withdrawn |
Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Ketamine
- Drug: Scopolamine
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale - 28 items
- Systematic Assessment for Treatment Emergent Events (SAFTEE)
|
0 |
All |
18 Years to 65 Years (Adult) |
NCT01613820 |
2012-P-000624 |
|
September 2015 |
February 2017 |
February 2017 |
June 7, 2012 |
February 19, 2018 |
|
- Depression Clinical and Reseach Program - MGH
Boston, Massachusetts, United States
|
| 16 |
NCT02890212 |
Recruiting |
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression |
|
- Dietary Supplement: selenium supplementation
- Dietary Supplement: placebo
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depressive Rating Scale
- Montgomery-Asberg Depression Rating Scale
- Clinical Global Impression Scale
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02890212 |
Selen-2015 |
|
August 2005 |
December 2017 |
December 2017 |
September 7, 2016 |
May 3, 2017 |
|
- Instituto de Psiquiatria - Hcfmusp
São Paulo, Brazil
|
| 17 |
NCT00361374 |
Completed
Has Results |
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression |
- Major Depressive Disorder
|
- Dietary Supplement: eicosapentaenoic acid
- Dietary Supplement: docosahexaenoic acid
- Drug: Placebo
|
Interventional |
Phase 3 |
- Massachusetts General Hospital
- Cedars-Sinai Medical Center
- National Institute of Mental Health (NIMH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Score on a Depression Severity Rating Scale Over Eight Weeks
|
196 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00361374 |
2005P002337
5R01MH074085 |
|
July 2006 |
February 2013 |
March 2013 |
August 8, 2006 |
July 18, 2014 |
July 18, 2014 |
- Depression Clinical Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 18 |
NCT00464711 |
Completed
Has Results |
Brain GABA Levels and Treatment Response in Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Mclean Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response and Remitter Status at Endpoint, Based on Change in Depression Severity Rating Scores
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT00464711 |
2006-P-001295 |
|
September 2006 |
September 2009 |
September 2009 |
April 24, 2007 |
January 4, 2017 |
January 4, 2017 |
- Depression Clinical and Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 19 |
NCT00633399 |
Completed
Has Results |
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs |
- Major Depressive Disorder
|
- Drug: Ziprasidone
- Drug: Placebo
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- University of Alabama at Birmingham
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2
- Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.
- Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8
|
458 |
All |
18 Years to 65 Years (Adult) |
NCT00633399 |
2007-P-002361 |
|
July 2008 |
March 2014 |
March 2014 |
March 12, 2008 |
July 3, 2014 |
July 3, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Massachusetts General Hospital- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
| 20 |
NCT00831415 |
Completed
Has Results |
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: desvenlafaxine succinate sustained release tablets
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score
- Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
- Number of Participants With Categorical Scores on Clinical Global Impression-Improvement (CGI-I)
- Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score
|
304 |
All |
20 Years and older (Adult, Senior) |
NCT00831415 |
3151A1-3350
B2061002 |
|
March 2009 |
March 2011 |
March 2011 |
January 29, 2009 |
January 30, 2012 |
January 30, 2012 |
- Pfizer Investigational Site
Aichi, Japan - Pfizer Investigational Site
Chiba, Japan - Pfizer Investigational Site
Fukuoka, Japan - (and 14 more...)
|
| 21 |
NCT00705185 |
Completed |
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational |
|
- Massachusetts General Hospital
- Precision Human Biolaboratories
- Cambridge Health Alliance
- (and 4 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- 16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult) |
NCT00705185 |
2007-P-002525 |
Bio-TestMDD |
April 2008 |
June 2010 |
June 2010 |
June 25, 2008 |
June 8, 2010 |
|
- University of Connecticut Health Center
Farmington, Connecticut, United States - Psychiatric Medicine Associates, L.L.C.
Chicago, Illinois, United States - Massachusetts General Hosptial
Boston, Massachusetts, United States - (and 2 more...)
|
| 22 |
NCT01244711 |
Terminated
Has Results |
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines |
- Major Depression
- Generalized Anxiety Disorder
|
|
Interventional |
Phase 4 |
- Weill Medical College of Cornell University
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale (MADRS)
|
1 |
All |
18 Years to 65 Years (Adult) |
NCT01244711 |
IRUSQUET0483 |
|
September 2008 |
September 2011 |
September 2011 |
November 19, 2010 |
April 3, 2015 |
March 6, 2015 |
- Weill Cornell Medical College
New York, New York, United States
|
| 23 |
NCT00300378 |
Completed |
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: desvenlafaxine 50 mg
- Drug: desvenlafaxine 100 mg
|
Interventional |
Phase 3 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary efficacy variable will be the change from baseline on the 17-item of the Hamilton Depression rating scale (HAM-D17 score) at the final on therapy evaluation
- The Global Clinical Improvement will be the key secondary efficacy variable.
|
480 |
All |
18 Years and older (Adult, Senior) |
NCT00300378 |
3151A1-333 |
|
March 2006 |
|
January 2007 |
March 8, 2006 |
December 5, 2007 |
|
- Rijeka, Croatia
- Split, Croatia
- Zagreb, Croatia
- (and 40 more...)
|
| 24 |
NCT00844974 |
Completed |
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms |
- Major Depression
- Bipolar Disorder
|
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- To examine the relationship between severity and type of depression with cognitive deficits
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT00844974 |
2007-p-001665 |
|
December 2007 |
December 2012 |
December 2012 |
February 16, 2009 |
November 18, 2013 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 25 |
NCT01337609 |
Terminated
Has Results |
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder |
- Major Depressive Disorder
- Irritable Bowel Syndrome
|
- Drug: Ganeden BC30
- Other: Placebo (sugar pill)
- Other: Ganeden BC30, Placebo (sugar pill)
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Ganeden Biotech, Inc.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
- IBS Severity Scoring System (IBS-SSS)
- Visual Analog Scale (VAS)
- (and 2 more...)
|
5 |
All |
18 Years to 65 Years (Adult) |
NCT01337609 |
2008P002387 |
|
June 2011 |
February 2012 |
February 2012 |
April 19, 2011 |
August 9, 2013 |
August 9, 2013 |
- Burlington Medical Associates
Burlington, Massachusetts, United States - Charles River Medical Associates
Westborough, Massachusetts, United States
|
| 26 |
NCT00321152 |
Completed |
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Other: 6(S)-5-MTHF (a Medical Food)
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Pamlab, L.L.C.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
150 |
All |
18 Years to 65 Years (Adult) |
NCT00321152 |
2006P000604 |
|
November 2006 |
August 2008 |
June 2010 |
May 3, 2006 |
June 8, 2010 |
|
- University of California San Diego School of Medicine
San Diego, California, United States - Rush University Medical Center, Psychiatric Medicine Associates, LLC
Chicago, Illinois, United States - Lousiana State University Health Sciences Center
New Orleans, Louisiana, United States - (and 8 more...)
|
| 27 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational |
|
- Massachusetts General Hospital
- ElMindA Ltd
- Massachusetts General Hospital
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
| 28 |
NCT00892463 |
Completed |
Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: Quetiapine (Seroquel) XR
|
Interventional |
Phase 4 |
- Sunnybrook Health Sciences Centre
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The QIDS-SR16 (Quick Inventory of Depressive Symptomatology - Self-report)
- HADS (Hamilton Anxiety Depression Scale) VADIS
|
26 |
All |
18 Years to 65 Years (Adult) |
NCT00892463 |
D1443L00072 |
|
May 2009 |
December 2010 |
December 2010 |
May 4, 2009 |
July 28, 2011 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
| 29 |
NCT01001559 |
Completed
Has Results |
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis |
- Major Depressive Disorder
|
- Drug: L-methylfolate
- Drug: Selective serotonin reuptake inhibitor (SSRI)
- Drug: Serotonin and norepinephrine reuptake inhibitor (SNRI)
|
Observational |
|
- Pamlab, Inc.
- Red Oak Psychiatry Associates, PA
- Baylor Health Care System
|
Industry / Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Improvement as Measured by Change in Clinical Global Impression of Severity (CGI-S) Rating From Baseline
- Length of Time to Peak Response, as Determined by the Clinical Global Impression of Severity (CGI-S) Scale
- Number of Hospitalizations Due to MDD
- Absolute Count of Alterations in Therapy Required, Such as Dose Increases, Antidepressant Substitutions, or Addition of Augmentation Medications
|
242 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01001559 |
Pamlab D-005 |
|
August 2009 |
December 2010 |
June 2011 |
October 26, 2009 |
December 19, 2013 |
December 19, 2013 |
- Red Oak Psychiatry Associates, PA
Houston, Texas, United States
|
| 30 |
NCT02048423 |
Unknown † |
An Open Prospective Trial of IV Ketamine in Suicidal Adolescents |
- Major Depressive Disorder
|
|
Interventional |
Phase 2
Phase 3 |
- Nationwide Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Quick Inventory of Depression Clinician (QIDS-C) total scores from baseline to endpoint and Clinical Global Improvement Score.
- Clinical Global Assessment Scale
|
10 |
All |
12 Years to 17 Years (Child) |
NCT02048423 |
IRB12-00445 |
|
June 2013 |
June 2015 |
June 2015 |
January 29, 2014 |
January 29, 2014 |
|
- Nationwide Children's Hospital
Columbus, Ohio, United States
|
| 31 |
NCT01309542 |
Completed |
Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Desvenlafaxine Succinate
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number (%) of Subjects Reporting Adverse Events during Treatment
- Number (%) of Subjects With Changes in Vital Signs (Blood Pressure, Pulse Rate, Weight) of Potential Clinical Importance
- Number (%) of Subjects With Laboratory Test Results (Hematology, Blood Chemistry, Lipid Profile, Urinalysis) of Potential Clinical Importance
- (and 4 more...)
|
1403 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01309542 |
3151A1-303
B2061069 |
|
August 2003 |
March 2006 |
March 2006 |
March 7, 2011 |
April 26, 2011 |
|
- Birmingham Research Group Inc.
Birmingham, Alabama, United States - Pivotal Research Centers 13128 North 94th Drive, Suite 200
Mesa, Arizona, United States - Pivotal Research
Peoria, Arizona, United States - (and 114 more...)
|
| 32 |
NCT00711737 |
Completed |
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months |
- Major Depression
- Generalized Anxiety Disorder
- Panic Disorder
|
|
Observational |
|
- Changi General Hospital
- Changi General Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
27 |
All |
21 Years and older (Adult, Senior) |
NCT00711737 |
2008.06 |
|
September 2008 |
October 2010 |
October 2010 |
July 9, 2008 |
June 17, 2011 |
|
- Changi General Hospital
Singapore, Singapore
|
| 33 |
NCT01310140 |
Terminated |
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features |
- Major Depressive Disorder
- Major Depressive Disorder w/ Psychotic Features
- Metabolic Syndrome
|
|
Observational |
|
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Massachusetts General Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The primary measure is any change in fasting insulin from admission to discharge while subjects are inpatient.
- The first secondary measure is a fasting lipid panel, including fasting total cholesterol, fasting LDL, fasting HDL, and fasting triglycerides; we want to measure a change in data from admission to discharge
- Fasting glucose will be a separate secondary outcome measure; we want to measure a change in data from admission to discharge
- (and 6 more...)
|
14 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01310140 |
2009-P-002723 |
|
January 2011 |
September 2012 |
September 2012 |
March 8, 2011 |
February 13, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 34 |
NCT01260649 |
Terminated
Has Results |
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression |
- Major Depressive Disorder
|
- Drug: ketamine
- Other: IV Saline
- Procedure: ECT
- (and 2 more...)
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Hamilton Depression Rating Scale - 28
- Number of Participants With Cognitive Side Effects
|
17 |
All |
18 Years to 65 Years (Adult) |
NCT01260649 |
2010P001672 |
|
November 1, 2010 |
October 26, 2012 |
November 1, 2012 |
December 15, 2010 |
May 22, 2017 |
April 14, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 35 |
NCT02165449 |
Recruiting |
Biomarkers of Fast Acting Therapies in Major Depression |
- Major Depressive Disorder
|
|
Interventional |
Phase 1 |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up
- Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- (and 7 more...)
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02165449 |
HS001796
K24MH102743
U01MH110008 |
|
June 2014 |
August 2020 |
August 2021 |
June 17, 2014 |
February 13, 2018 |
|
- Geffen School of Medicine, UCLA
Los Angeles, California, United States
|
| 36 |
NCT02553915 |
Recruiting |
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach |
- Major Depressive Disorder
- Overweight
- Inflammation
|
- Other: Placebo
- Drug: EPA 1 g/day
- Drug: EPA 2 g/day
- Drug: EPA 4 g/day
|
Interventional |
Phase 2
Phase 3 |
- Massachusetts General Hospital
- Emory University
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change in plasma concentration of inflammatory biomarkers
- Mean change in depression severity score
- Mean change in plasma concentration of mitogen-stimulated PBMC IL-6
- (and 2 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02553915 |
R01AT008857-01 |
|
December 2015 |
June 2018 |
June 2018 |
September 18, 2015 |
August 29, 2017 |
|
- Emory University School of Medicine
Atlanta, Georgia, United States - Depression Clinical and Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 37 |
NCT00731653 |
Completed
Has Results |
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: Combination Product: BCI-024 + BCI-049
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- BrainCells Inc.
- Massachusetts General Hospital
|
Other / Industry |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Primary Safety and Tolerability Outcome Measure is Reported Adverse Events.
|
81 |
All |
18 Years to 65 Years (Adult) |
NCT00731653 |
CBM-IT-01-EXT |
|
July 2008 |
December 2008 |
January 2009 |
August 11, 2008 |
December 17, 2013 |
December 17, 2013 |
- Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States - Synergy Research Centers
San Diego, California, United States - Atlanta Institute of Medicine & Research, Inc.
Altanta, Georgia, United States - (and 6 more...)
|
| 38 |
NCT00955474 |
Terminated
Has Results |
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms |
- Major Depressive Disorder With Psychotic Features
|
- Drug: Quetiapine
- Drug: escitalopram
- Drug: Sertraline
- Drug: Citalopram
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression
- Psychosis
- Fasting Blood Glucose
- (and 12 more...)
|
32 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT00955474 |
2008P001022 |
Seroquel |
September 2008 |
January 2013 |
January 2013 |
August 10, 2009 |
April 20, 2017 |
March 28, 2016 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 39 |
NCT00961454 |
Completed |
Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression |
- Major Depression
- Anxiety Disorder
- Post-Traumatic Stress Disorder
- Substance Abuse Disorder
|
- Device: Photobiomodulation with a super-luminous light emitting diode
|
Interventional |
Phase 1 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale
- Hamilton Anxiety Rating Scale
|
10 |
All |
18 Years to 60 Years (Adult) |
NCT00961454 |
2008P-000937 |
|
January 2009 |
June 2009 |
June 2009 |
August 19, 2009 |
August 19, 2009 |
|
- Wellman Center for Photomedicine, Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 40 |
NCT02473783 |
Completed
Has Results |
The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD |
- Major Depressive Disorder
|
- Drug: Sertraline HCl
- Other: I-123-ADAM SPECT
|
Interventional |
Phase 2 |
- Tri-Service General Hospital
- Institute of Nuclear Energy Research, Taiwan
- Tri-Service General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The SERT Binding Potential (BP) --(Only the Treatment Group Was Assessed)
- Hamilton Depression Rating Scale (HAM-D) Total Scores
- Safety Assessments - the Tolerability of Injection of I-123-ADAM Solution
|
37 |
All |
20 Years to 65 Years (Adult) |
NCT02473783 |
INEI-1A20090409 |
STAPMDDTDM |
October 2011 |
November 2012 |
November 2012 |
June 17, 2015 |
January 19, 2018 |
December 21, 2017 |
|
| 41 |
NCT00824044 |
Completed
Has Results |
Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression |
- Major Depressive Disorder
|
- Behavioral: Cognitive Behavioral Therapy (CBT)
- Drug: Escitalopram
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Hamilton Depression Rating Scale (HAM-D-17) Scores
- Change in Absolute Beta Power in Channel 4
- Change in Absolute Theta Power From Channel 1
- (and 7 more...)
|
39 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00824044 |
2008-P-000838 |
|
July 2008 |
March 2011 |
March 2011 |
January 16, 2009 |
January 5, 2018 |
January 8, 2013 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 42 |
NCT01254305 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Paroxetine, Sertraline, Citalopram or Fluoxetine.
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
- Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
- Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
|
262 |
All |
18 Years to 65 Years (Adult) |
NCT01254305 |
LVM-MD-06 |
|
April 2011 |
July 2012 |
July 2012 |
December 6, 2010 |
August 6, 2014 |
August 6, 2014 |
- Forest Investigative Site 010
Birmingham, Alabama, United States - Forest Investigative Site 002
Little Rock, Arkansas, United States - Forest Investigative Site 001
Cerritos, California, United States - (and 17 more...)
|
| 43 |
NCT01147913 |
Completed |
Computerized Information-Processing Bias Retraining in Depressed Adolescents |
|
- Behavioral: Computerized Information-Processing Bias Retraining
- Behavioral: Attention Control Training
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Test of Interpretation Bias (TIB)
- Test of Interpretation Bias
- Kiddie-Schedule of Affective Disorders and Schizophrenia-Epidemiologic Version (K-SADS-E; Orvaschek & Puig-Antich, 1987)
- (and 5 more...)
|
48 |
All |
14 Years to 21 Years (Child, Adult) |
NCT01147913 |
F32MH088065-01 |
|
March 2010 |
April 2012 |
April 2012 |
June 22, 2010 |
May 3, 2012 |
|
- Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital
Cambridge, Massachusetts, United States
|
| 44 |
NCT00361218 |
Completed
Has Results |
Biological Markers of Response to Treatment in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: open-label selective serotonin reuptake inhibitor (SSRI)
|
Interventional |
Phase 3 |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum Brain-derived Neurotrophic Factor (BDNF) Levels
- Quantitative Electroencephalogram Measurements
|
72 |
All |
18 Years to 65 Years (Adult) |
NCT00361218 |
2005P000413 |
|
October 2005 |
December 2008 |
December 2008 |
August 8, 2006 |
November 21, 2017 |
September 26, 2013 |
|
| 45 |
NCT01326793 |
Completed |
Internet-Based Depression Screening for College Students |
- Major Depressive Disorder
|
- Other: Skype Consultation
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- 9-item Patient Health Questionnaire
|
1900 |
All |
18 Years and older (Adult, Senior) |
NCT01326793 |
2008P001438 |
|
September 2008 |
December 2014 |
December 2014 |
March 31, 2011 |
April 28, 2015 |
|
- Depression Clinical and Research Program at Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 46 |
NCT03057691 |
Recruiting |
The Impact of Depression and/or Anxiety on PCI Patients |
- Acute Coronary Syndrome
- MAjor Depressive Disorder
- Generalized Anxiety Disorder
|
- Other: antidepressive and anti-anxiety therapy
|
Observational |
|
- First Affiliated Hospital Xi'an Jiaotong University
- Shaanxi Provincial People's Hospital
- Xi An No.1 Hospital
- (and 8 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Major Adverse Cardiovascular Events
- all-cause mortality
- heart failure
- (and 6 more...)
|
5000 |
All |
24 Years and older (Adult, Senior) |
NCT03057691 |
XJTU1AF-CRF-2016-004 |
|
March 11, 2017 |
December 2019 |
January 2020 |
February 20, 2017 |
March 2, 2018 |
|
- First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
| 47 |
NCT01464229 |
Completed
Has Results |
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability |
- Major Depressive Disorder
|
- Drug: Iloperidone
- Drug: Placebo
|
Interventional |
Phase 4 |
- Maurizio Fava, MD
- Novartis Pharmaceuticals
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
20 |
All |
18 Years to 65 Years (Adult) |
NCT01464229 |
2011P002043 |
|
April 2012 |
December 2014 |
December 2014 |
November 3, 2011 |
April 11, 2017 |
April 11, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 48 |
NCT02715778 |
Enrolling by invitation |
Translational Investigation of Gestational Environment on Neurobehavioral Function in Children |
- Major Depressive Disorder
|
|
Observational |
|
- Massachusetts General Hospital
- Massachusetts General Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Cross-Sectional
|
- neuropsychological functioning as assessed by CANTAB research battery
|
100 |
All |
6 Years and older (Child, Adult, Senior) |
NCT02715778 |
2015P001326 |
|
February 2016 |
September 2017 |
June 2019 |
March 22, 2016 |
January 18, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Boston Children's Hospital
Boston, Massachusetts, United States
|
| 49 |
NCT02253225 |
Recruiting |
Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study |
- Bipolar Disorder
- Major Depression
- Rumination
|
- Other: Functional Magnetic Resonance Imaging (fMRI)
|
Observational |
|
- Massachusetts General Hospital
- Brain & Behavior Research Foundation
- Massachusetts General Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Functional Magnetic Resonance Imaging (fMRI) to examine self processing and self focus
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02253225 |
2012P000714
19531 |
|
January 2013 |
August 2018 |
January 2019 |
October 1, 2014 |
August 29, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 50 |
NCT00157547 |
Completed |
Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression |
- Major Depressive Disorder
|
- Drug: Selective serotonin reuptake inhibitors (SSRI)
|
Interventional |
Phase 4 |
- Massachusetts General Hospital
- Medtronic - MITG
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
95 |
All |
18 Years to 65 Years (Adult) |
NCT00157547 |
2002-P-001784 |
|
April 2003 |
August 2006 |
August 2006 |
September 12, 2005 |
May 28, 2008 |
|
|
Create an RSS feed from your search for:
Download the search results for: